University of Toledo Secures $3.7 Million Lyme Grant

The National Institute of Allergy and Infectious Diseases is funding research to develop a new Lyme disease vaccine.

Updated on Oct. 21, 2026 in Life Sciences

University of Toledo Secures $3.7 Million Lyme Grant

Live Poll

Should federal research funding prioritize vaccines for diseases with high annual infection rates?

The University of Toledo has been awarded a $3.7 million grant from the National Institute of Allergy and Infectious Diseases to continue work on a Lyme disease vaccine. The five-year project aims to create a viable immunization after the previous vaccine was pulled from the market in 2002.

Why it matters

With approximately 476,000 Americans diagnosed with Lyme disease annually, there is an urgent need for preventative measures as tick ranges continue to expand into Ohio. This research seeks to fill the gap left by the absence of any currently available vaccine in the United States.

The study utilizes a vaccine strain engineered to trap bacteria by preventing reverse movement, allowing the immune system to clear the infection. The grant covers a five-year period to support the research team's refinement of this unconventional approach.

The players

Dr. Mark Wooten

He is the lead researcher at the University of Toledo who has a 25-year history of training scientists in the field.

National Institute of Allergy and Infectious Diseases

This federal agency is part of the National Institutes of Health and conducts research to better understand and prevent infectious diseases.

The details

Dr. Mark Wooten is leading the development of the vaccine, which forces bacteria into a state where they can only move forward and become trapped. The funding will support the employment of research associates, postdoctoral researchers, and students at the Toledo facility.

The University of Toledo announced the grant on October 21, 2026.
The previous vaccine, LYMErix, was removed from the market in 2002.

The Big Picture

This research initiative serves as a direct effort to restore preventative medical options after the 2002 market withdrawal of LYMErix. It shifts the discipline toward unconventional vaccine strains that target bacterial mobility rather than traditional protein markers.

A successful vaccine could provide residents in Ohio and across the U.S. with a critical defense against a disease currently affecting 476,000 people each year. The development could eventually change how local communities approach outdoor activities in areas with growing tick populations.

The takeaway

While the project is in the research and testing phase, it represents a major step toward filling a decades-long void in Lyme disease prevention. Residents should continue to follow current tick-bite prevention protocols as no vaccine is yet available for public use.